Comparison of Holmium Laser Enucleation of the Prostate and Robotic Water Jet Ablation for Benign Prostatic Hyperplasia
Prospective Randomized Controlled Comparison of Holmium Laser Enucleation of the Prostate With Robotic Water Jet Ablation
調査の概要
状態
詳細な説明
This prospective, randomized controlled trial is designed to compare the safety, effectiveness, and long-term durability of Holmium Laser Enucleation of the Prostate (HoLEP) utilizing MOSES 2.0 technology with Robotic Water Jet Ablation (RWJA) performed using the Hydros Robotic System for the treatment of benign prostatic hyperplasia (BPH). The trial will enroll 100 men aged 50 to 80 years who present with moderate-to-severe lower urinary tract symptoms secondary to BPH and prostate volumes between 50 and 180 mL. Participants will be randomized in a 1:1 ratio to receive either HoLEP or RWJA and will be monitored for five years following treatment.
The primary objective is to compare objective measures of treatment efficacy and durability at 12 months, specifically changes in prostate volume, prostate-specific antigen (PSA) levels, urinary flow rate (Qmax), and post-void residual urine volume (PVR). Secondary objectives include assessment of perioperative outcomes, safety profiles, patient-reported urinary and sexual function, treatment durability, reintervention rates, and healthcare resource utilization. Outcomes will be measured using validated instruments, such as the International Prostate Symptom Score (IPSS), Sexual Health Inventory for Men (SHIM), Male Sexual Health Questionnaire-Ejaculatory Dysfunction (MSHQ-EjD), and Incontinence Severity Index (ISI).
Although both procedures are established and FDA-approved therapies for BPH, direct comparative evidence is limited. This study seeks to address this evidence gap by generating high-quality comparative effectiveness data to inform clinical decision-making and patient counseling. The results may clarify the relative benefits and tradeoffs of each procedure, particularly in terms of symptom improvement, preservation of sexual function, durability of treatment response, and long-term healthcare utilization.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Hazem Elmansy, MD
- 電話番号:346-516-1481
- メール:hmelmansy@houstonmethodist.org
研究連絡先のバックアップ
- 名前:Miguel Valdivia y Alvarado, MD
- 電話番号:346-356-3622
- メール:mvaldiviayalvarado@houstonmethodist.org
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77030
- Houston Methodist
-
コンタクト:
- Hazem Elmansy, MD
- 電話番号:346-516-1481
- メール:hmelmansy@houstonmethodist.org
-
コンタクト:
- Miguel Valdivia y Alvarado, MD
- 電話番号:346-356-3622
- メール:mvaldiviayalvarado@houstonmethodist.org
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Male, age 50-80 years
- International Prostate Symptom Score (IPSS) ≥ 12
- Prostate size (TRUS): 50-180 mL
- Diagnosis of LUTS due to BPH
- Uroflow Qmax ≤ 15 mL/sec
- Mentally capable, able to comply with study procedures, written informed consent provided
- Able to follow study instructions and complete all required visits
Exclusion Criteria:
- BMI ≥ 42
- History of prostate cancer
- Suspected or history of bladder cancer
- Active or untreated bladder stones at screening
- Indwelling catheter for more than 3 months before baseline
- Active urinary tract infection
- History of urethral stricture or bladder neck stenosis
- Damage to the external urethral sphincter
- Previous prostate surgery or lower urinary tract surgery
- Use of obligatory anticoagulants (if not stoppable) or known coagulopathy (except ASA 100 mg/d)
- Contraindications to general and spinal anesthesia
- Any condition that could interfere with study participation or outcomes, per investigator judgment
- Lacks legal or mental capacity to consent
- Simultaneous participation in another therapeutic urological trial
- Known or persistent abuse of medication, drugs, or alcohol
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:HoLEP with MOSES 2.0
Holmium laser enucleation of the prostate using MOSES 2.0 pulse-modulation technology, performed per institutional standard of care.
|
Holmium laser enucleation of the prostate using MOSES 2.0 pulse-modulation technology, performed per institutional standard of care.
|
|
アクティブコンパレータ:RWJA with Hydros Robotic System
Robotic-assisted waterjet ablation of the prostate using the Hydros Robotic System, performed per institutional standard of care.
|
Device - RWJA (Hydros Robotic System) / Aquablation therapy (often referred to by its commercial name, "Aquablation").
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Prostate Volume
時間枠:Baseline and 12 months post-intervention
|
Measured via transrectal ultrasound (TRUS); change from baseline.
|
Baseline and 12 months post-intervention
|
|
Change in Prostate-Specific Antigen (PSA)
時間枠:Baseline and 12 months post-intervention
|
Serum PSA level; change from baseline.
|
Baseline and 12 months post-intervention
|
|
Change in Urinary Flow Rate (Qmax)
時間枠:Baseline and 12 months post-intervention
|
Peak urinary flow rate via uroflowmetry; change from baseline.
|
Baseline and 12 months post-intervention
|
|
Change in Post-Void Residual Volume (PVR)
時間枠:Baseline and 12 months post-intervention
|
Bladder scan-measured PVR; change from baseline.
|
Baseline and 12 months post-intervention
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence and Severity of Adverse Events
時間枠:From patient hospital discharge through 3 and 12 months post-surgery
|
Adverse events graded by the Clavien-Dindo classification system.
|
From patient hospital discharge through 3 and 12 months post-surgery
|
|
Operative Time
時間枠:Day (duration) of surgical procedure
|
Total procedure time, start to finish.
|
Day (duration) of surgical procedure
|
|
Hemostasis Time
時間枠:Day (duration) of surgical procedure
|
Time required to achieve hemostasis intraoperatively.
|
Day (duration) of surgical procedure
|
|
Perioperative Change in Hemoglobin
時間枠:Baseline to immediate postoperative period (when patient is in the recovery room post surgery)
|
Hemoglobin level change from baseline to immediate postoperative measurement.
|
Baseline to immediate postoperative period (when patient is in the recovery room post surgery)
|
|
Time to Catheter-Free Status
時間枠:From surgery day until catheter removal
|
Duration from end of surgery to catheter removal.
|
From surgery day until catheter removal
|
|
Length of Hospital Stay / Discharge Time
時間枠:Day of surgical procedure through hospital discharge
|
Time from surgery to hospital discharge.
|
Day of surgical procedure through hospital discharge
|
|
Change in IPSS/QoL Score
時間枠:Baseline, 3, 6, and 12 months post-surgery
|
International Prostate Symptom Score / Quality of Life index.
|
Baseline, 3, 6, and 12 months post-surgery
|
|
Change in SHIM Score
時間枠:Baseline, 3, 6, and 12 months post-surgery
|
Sexual Health Inventory for Men.
|
Baseline, 3, 6, and 12 months post-surgery
|
|
Change in MSHQ-EjD Score
時間枠:Baseline, 3, 6, and 12 months post-surgery
|
Male Sexual Health Questionnaire - Ejaculatory Dysfunction.
|
Baseline, 3, 6, and 12 months post-surgery
|
|
Change in Incontinence Outcomes
時間枠:Baseline, 3, 6, and 12 months post-surgery
|
Incontinence Severity Index (ISI) score and Cough Stress Test (CST) result.
|
Baseline, 3, 6, and 12 months post-surgery
|
|
Long-Term Durability of Functional Improvements
時間枠:24, 36, 48, and 60 months post-intervention
|
Composite tracking of IPSS, Qmax, PVR, PSA, and prostate volume.
|
24, 36, 48, and 60 months post-intervention
|
|
Post-Operative Medication Use
時間枠:Through 60 months post-intervention
|
Number of prescriptions written and filled (initial fills and refills), e.g., alpha-blockers, 5-alpha reductase inhibitors.
|
Through 60 months post-intervention
|
|
Reintervention Rate
時間枠:Through 60 months post-intervention
|
Repeat procedures or additional therapies for BPH/LUTS.
|
Through 60 months post-intervention
|
|
Unplanned Healthcare Encounters
時間枠:Through 60 months post-intervention
|
Emergency visits, urgent care visits, and add-on clinic visits related to the procedure.
|
Through 60 months post-intervention
|
|
Incidence of Urethral Stricture Requiring Intervention
時間枠:Through 60 months post-intervention
|
New urethral stricture or bladder neck stenosis requiring treatment.
|
Through 60 months post-intervention
|
|
Unanticipated Advanced Diagnostics
時間枠:Through 60 months post-intervention
|
Unplanned MRI, cystoscopy, or prostate cancer biomarker testing.
|
Through 60 months post-intervention
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- Pro00041304
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。